Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: a strategy to improve the quality of gynecologic cancer clinical research

Editorial

Maurie Markman. Gynecol Oncol. 2008 Sep.

. 2008 Sep;110(3):275-7.

doi: 10.1016/j.ygyno.2008.05.014. Epub 2008 Jun 30.

No abstract available

Similar articles

Carboplatin versus cisplatin in ovarian cancer.
Alberts DS. Alberts DS. Semin Oncol. 1995 Oct;22(5 Suppl 12):88-90. Semin Oncol. 1995. PMID: 7481869 Review.
Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
Ozols RF. Ozols RF. Semin Oncol. 2000 Jun;27(3 Suppl 7):3-7. Semin Oncol. 2000. PMID: 10952119 Review.
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C. du Bois A, et al. Semin Oncol. 1997 Aug;24(4 Suppl 11):S11-28-S11-33. Semin Oncol. 1997. PMID: 9314296 Clinical Trial.
[Pharmacotherapy in ovarian carcinoma].
Pfisterer J, Du Bois A. Pfisterer J, et al. MMW Fortschr Med. 2005 Oct 27;147(43):34-6. MMW Fortschr Med. 2005. PMID: 16302419 Review. German.
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, Nitz U, Jackisch C. du Bois A, et al. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-44-S15-52. Semin Oncol. 1997. PMID: 9346222 Clinical Trial.